Loading
Lung Metastases / Lung Cancer / Abenacianine · Phase 3 Trial
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 clinical trial registry record for abenacianine, a tumor-targeted fluorescent imaging agent for lung cancer detection during surgery. No results have been posted; the study is currently recruiting participants. The planned design is rigorous, but efficacy and safety data are not yet available.
Phase 3, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Lung Cancer, Lung Metastases; age from 18 Years. Intervention: Abenacianine with surgery using Standard of Care (SOC) only; Abenacianine with surgery using Standard of Care plus Near…. Compared with: Abenacianine without NIR imaging (control). n = 132. 9 sites: United States, Australia.
This is a Phase 3 clinical trial registry record for abenacianine, a tumor-targeted fluorescent imaging agent for lung cancer detection during surgery. No results have been posted; the study is currently recruiting participants. The planned design is rigorous, but efficacy and safety data are not yet available.
No efficacy, safety, or outcome data are available to assess.
The source did not state who this applies to in practice.
This is a Phase 3 registry record with no posted results; the study is actively recruiting and design details do not yet support efficacy or safety claims.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07499674). This is a study registration, not published results. Lead sponsor: Vergent Bioscience, Inc.. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 132 participants (ESTIMATED). Conditions: Lung Cancer, Lung Metastases. Interventions: DRUG: Abenacianine; OTHER: Near Infrared (NIR) Imaging. Primary outcome measures: Identify the proportion of participants with at least one Clinically Significant Event (CSE) as defined by: , Day of Surgery. Brief summary: This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.